Live Earnings Conference Call: Tarsus Pharmaceuticals will host a live Q1 2025 earnings call on May 1, 2025 at 4:30PM ET. Follow this link to get details and listen to Tarsus Pharmaceuticals' Q1 2025 earnings call when it goes live. Get details. Tarsus Pharmaceuticals (TARS) Competitors $51.91 +1.01 (+1.98%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. ROIV, LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, and AXSMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Tarsus Pharmaceuticals (NASDAQ:TARS) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Which has higher valuation & earnings, TARS or ROIV? Roivant Sciences has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M10.89-$135.89M-$3.10-16.75Roivant Sciences$122.59M67.64$4.35B-$0.15-77.47 Do institutionals & insiders have more ownership in TARS or ROIV? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer TARS or ROIV? Tarsus Pharmaceuticals presently has a consensus price target of $63.67, suggesting a potential upside of 22.65%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 50.60%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to TARS or ROIV? In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 13 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.63 beat Tarsus Pharmaceuticals' score of 1.37 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is TARS or ROIV more profitable? Tarsus Pharmaceuticals has a net margin of -103.64% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-103.64% -55.86% -39.28% Roivant Sciences -119.54%-14.05%-12.81% Which has more volatility & risk, TARS or ROIV? Tarsus Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Does the MarketBeat Community prefer TARS or ROIV? Roivant Sciences received 3 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 78.57% of users gave Roivant Sciences an outperform vote while only 68.42% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTarsus PharmaceuticalsOutperform Votes5268.42% Underperform Votes2431.58% Roivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% SummaryRoivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-13.6230.4222.4818.48Price / Sales10.89498.92394.56103.59Price / CashN/A168.6838.1834.62Price / Book8.723.206.774.25Net Income-$135.89M-$72.35M$3.22B$248.23M7 Day Performance3.88%1.46%1.48%0.89%1 Month Performance6.11%8.79%3.99%3.53%1 Year Performance59.77%-22.36%16.15%5.08% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.3696 of 5 stars$51.91+2.0%$63.67+22.6%+65.2%$1.99B$182.95M-13.6250Upcoming EarningsPositive NewsROIVRoivant Sciences2.1666 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860LNTHLantheus3.9823 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7636 of 5 stars$36.56-0.5%$66.67+82.3%+8.3%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$33.51-1.1%$53.00+58.2%+49.7%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageLEGNLegend Biotech2.6249 of 5 stars$32.24-1.7%$79.00+145.0%-20.1%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3378 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsPositive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines2.5598 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Analyst ForecastPositive NewsSRPTSarepta Therapeutics4.678 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.8386 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive News Related Companies and Tools Related Companies Roivant Sciences Alternatives Lantheus Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts